[
    {
        "content": "NEW YORK  Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy  and on Thursday changed its reimbursement policy on its website to \"medically necessary.\"",
        "date": "11092017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment "
    },
    {
        "content": "NEW YORK  Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy  and on Thursday changed its reimbursement policy on its website to \"medically necessary.\"",
        "date": "11092017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment "
    },
    {
        "content": "* Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024",
        "date": "11072017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes "
    },
    {
        "content": "* Sarepta Therapeutics and Nationwide Children\u2019s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program for the treatment of duchenne muscular dystrophy Source text for Eikon: Further company coverage:",
        "date": "11062017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics and Nationwide Children\u2019s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program "
    },
    {
        "content": "* Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate  srp-5051",
        "date": "11072017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate  srp-5051 "
    },
    {
        "content": "* Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD)",
        "date": "10312017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics signs exclusive global collaboration with Duke University "
    },
    {
        "content": "* Sarepta Therapeutics appoints Guriqbal Basi  Ph.D. as Chief Scientific Officer Source text for Eikon: Further company coverage:",
        "date": "09252017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics appoints Chief Scientific Officer "
    },
    {
        "content": "Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.",
        "date": "09062017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Sarepta's shares jump on new DMD drug's promising trial results "
    },
    {
        "content": "Sept 6 Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.",
        "date": "09062017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-Sarepta's shares jump on new DMD drug's promising trial results "
    },
    {
        "content": "Sept 6 Sarepta Therapeutics Inc's shares jumped about 15 percent on Wednesday after the company's drug to treat patients with a form of a fatal muscle-wasting disease met the main goal of an early-stage trial.",
        "date": "09062017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta shares rise as new DMD drug succeeds early stage trial "
    },
    {
        "content": "* Sarepta Therapeutics announces positive results in its study evaluating gene expression  dystrophin production  and dystrophin localization in patients with duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053)",
        "date": "09062017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics reports positive results in study "
    },
    {
        "content": "A federal appeals court on Tuesday upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading investors about the likelihood that its flagship treatment for a rare muscle disorder would gain regulatory approval.",
        "date": "08222017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Sarepta Therapeutics defeats investor lawsuit on appeal "
    },
    {
        "content": "* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing",
        "date": "08142017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Paulson & Co takes share stake in Apple  dissolves share stake in Sarepta  Biogen "
    },
    {
        "content": "* Sarepta Therapeutics announces proposed $250 million public offering of common stock",
        "date": "07242017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics announces proposed $250 mln public offering of common stock "
    },
    {
        "content": "* Sarepta Therapeutics announces pricing of $325 million public offering of common stock",
        "date": "07252017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics announces pricing of $325 mln public offering of common stock "
    },
    {
        "content": "* Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with duchenne muscular dystrophy amenable to exon 51 skipping",
        "date": "07192017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics and Clinigen launch managed access program "
    },
    {
        "content": "Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported much better-than-expected quarterly sales of its Duchenne muscular dystrophy (DMD) drug as the launch of the treatment steamrolls on.",
        "date": "07202017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Sarepta surges after stellar DMD drug powers on "
    },
    {
        "content": "* Sarepta Therapeutics secures $100 million in debt financing",
        "date": "07182017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics secures $100 million in debt financing "
    },
    {
        "content": "July 20 Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported much better-than-expected quarterly sales of its Duchenne muscular dystrophy (DMD) drug as the launch of the treatment steamrolls on.",
        "date": "07202017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-Sarepta surges after stellar DMD drug powers on "
    },
    {
        "content": "* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation",
        "date": "07182017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta and Biomarin report execution of global settlement "
    },
    {
        "content": "July 20 Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported strong quarterly sales of its drug to treat Duchenne muscular dystrophy (DMD).",
        "date": "07202017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta surges after robust DMD drug sales "
    },
    {
        "content": "June 28 Sarepta Therapeutics Inc said on Wednesday it appointed Douglas Ingram as president and chief executive officer.",
        "date": "06282017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta appoints former Allergan executive Douglas Ingram as CEO "
    },
    {
        "content": "* Sarepta Therapeutics appoints Douglas S. Ingram as president and chief executive officer Source text for Eikon: Further company coverage:",
        "date": "06282017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics appoints Douglas Ingram as president  CEO "
    },
    {
        "content": "* Sarepta Therapeutics and Genethon announce a gene therapy research collaboration for the treatment of Duchenne Muscular Dystrophy",
        "date": "06212017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta  Genethon announce research collaboration for DMD treatment "
    },
    {
        "content": "LAS VEGAS Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.",
        "date": "05182017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Tourbillon's Karp says Sarepta shares could surge 200 percent "
    },
    {
        "content": "LAS VEGAS  May 18 Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.",
        "date": "05182017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Tourbillon's Karp says Sarepta shares could surge 200 pct "
    },
    {
        "content": "* Sarepta Therapeutics - in Q1  recognized net revenues of $16.3 million in product sales; no revenue was recognized for the same period of 2016",
        "date": "04272017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics anticipates net revenues for the year to exceed $95 mln "
    },
    {
        "content": "* Sarepta Therapeutics announces addition of Kenneth Fischbeck  M.D. And matthew wood M.D.  Ph.D. to the company\u2019s strategic and scientific advisory board Source text for Eikon: Further company coverage:",
        "date": "03302017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta appoints Kenneth Fischbeckt to the company\u2019s strategic and scientific advisory board "
    },
    {
        "content": "* Sarepta Therapeutics announces fourth quarter and full-year 2016 financial results and recent corporate developments",
        "date": "02282017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics Q4 non-gaap loss per share $0.71 "
    },
    {
        "content": "* Sarepta Therapeutics agrees to sale of priority review voucher for $125m",
        "date": "02212017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln "
    },
    {
        "content": "* Sarepta Therapeutics enters into license agreement with nationwide children's hospital for GALGT2 gene therapy program  Source text for Eikon:  Further company coverage:",
        "date": "01102017",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics enters into license agreement with nationwide children's hospital "
    },
    {
        "content": "NEW YORK  Nov 11 Biotechnology companies  whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election  may soon see another benefit: an uptick in biotech M&A.",
        "date": "11112016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "RPT-Trump presidency could prove a salve for pharma merger deals "
    },
    {
        "content": "NEW YORK  Nov 11 Biotechnology companies  whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election  may soon see another benefit: an uptick in biotech M&A.",
        "date": "11112016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Trump presidency could prove a salve for pharma merger deals "
    },
    {
        "content": "* Sarepta Therapeutics announces third quarter 2016 financial results and recent corporate developments",
        "date": "10272016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics Q3 loss per share $1.18 "
    },
    {
        "content": "Oct 7 Health insurer Anthem Inc said it would not cover the first U.S. Food and Drug Administration-approved Duchenne muscular dystrophy (DMD) drug  developed by Sarepta Therapeutics Inc  calling it \"investigational and not medically necessary\".",
        "date": "10072016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Anthem won't cover first FDA-approved Duchenne drug "
    },
    {
        "content": "Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.",
        "date": "10042016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Sarepta partners with UK's Summit on Duchenne drugs "
    },
    {
        "content": "Oct 4 Sarepta Therapeutics Inc said it secured the European rights to Summit Therapeutics Plc's  experimental Duchenne muscular dystrophy (DMD) drug as it looks to build on its lead in treating the fatal muscle-wasting disease.",
        "date": "10042016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 3-Sarepta partners with UK's Summit on Duchenne drugs "
    },
    {
        "content": "* Collaboration agreement with Sarepta also contains a standstill provision - SEC filing",
        "date": "10042016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Summit's agreement with Sarepta also contains a standstill provision "
    },
    {
        "content": "* Sarepta Therapeutics announces pricing of $300 million public offering of common stock",
        "date": "09222016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics reports pricing of $300 million public offering of common stock "
    },
    {
        "content": "* Sarepta Therapeutics announces proposed public offering of common stock",
        "date": "09212016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics announces offering to sell up to $225 mln of stock "
    },
    {
        "content": "Bowing to pressure from patient advocates  the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy.",
        "date": "09192016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Bowing to pressure  FDA approves Sarepta's Duchenne drug "
    },
    {
        "content": "Sept 19 Bowing to pressure from patient advocates  the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy.",
        "date": "09192016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 3-Bowing to pressure  U.S. FDA approves Sarepta's Duchenne drug "
    },
    {
        "content": "* Sarepta therapeutics announces fda accelerated approval of exondys 51(tm) (eteplirsen) injection  an exon skipping therapy to treat duchenne muscular dystrophy (dmd) patients amenable to skipping exon 51",
        "date": "09192016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics says U.S. Commercial launch for Exondys 51 planned to commence immediately "
    },
    {
        "content": "Sept 19 Sarepta Therapeutics Inc's  Duchenne muscular dystrophy drug won approval from the U.S. Food and Drug Administration on Monday  capping months of regulatory uncertainty and pressure from parents and patient advocates to endorse it.",
        "date": "09192016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta's keenly watched muscle dystrophy drug wins FDA approval "
    },
    {
        "content": "Sept 14 Shares of Sarepta Therapeutics Inc  rose as much as 29 percent after a key critic of its muscle-wasting drug left the U.S. Food and Drug Administration ahead of the agency's decision whether to approve it.",
        "date": "09142016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta jumps on drug approval hopes after FDA critic departs "
    },
    {
        "content": "Sept 14 Shares of Sarepta Therapeutics Inc  rose as much as 29 percent after a key critic of its muscle-wasting drug left the U.S. Food and Drug Administration ahead of the agency's decision whether to approve it.",
        "date": "09142016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-Sarepta jumps on drug approval hopes after FDA critic departs "
    },
    {
        "content": "* No revenue was recognized for three months ended June 30  2016 and 2015",
        "date": "07192016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics Q2 non-GAAP loss per share $1.19 excluding items "
    },
    {
        "content": "* Sarepta Therapeutics Inc says intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering",
        "date": "06082016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics announces proposed offering "
    },
    {
        "content": "June 6 Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has requested for additional data from an ongoing study for its muscle-wasting treatment as the agency decides whether to approve the drug or not.",
        "date": "06062016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "UPDATE 2-Sarepta says FDA asks for more data for its muscle-wasting treatment "
    },
    {
        "content": "June 6 Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has requested for additional data for its muscle-wasting treatment as the agency decides whether to approve the drug or not.",
        "date": "06062016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta says FDA asks for more data for its muscle-wasting treatment "
    },
    {
        "content": "* Sarepta Therapeutics announces FDA request for dystrophin data prior to making a decision on eteplirsen NDA",
        "date": "06062016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics announces FDA request for dystrophin data "
    },
    {
        "content": "June 2 The U.S. Food and Drug Administration said companies could only charge patients for the cost of manufacturing experimental treatments used under compassionate grounds  and it cannot force government or private health insurers to pay for these drugs.",
        "date": "06022016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-Experimental drugs for compassionate use to sell only at cost: FDA "
    },
    {
        "content": "June 2 The U.S. Food and Drug Administration said companies could only charge patients for the cost of manufacturing experimental treatments used under compassionate grounds  and it cannot force government or private health insurers to pay for these drugs.",
        "date": "06022016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Drugmakers can't charge beyond making costs for compassionate use: FDA "
    },
    {
        "content": "May 25 Sarepta Therapeutics Inc said it was notified by the U.S. Food and Drug Administration that a review of its muscle-wasting disorder drug would not be completed by Thursday.",
        "date": "05252016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "FDA delays decision on Sarepta's muscle-wasting disorder drug "
    },
    {
        "content": "* Analysts say chances of approval still low   (Updates shares  adds CureDuchenne comment)",
        "date": "05252016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 3-FDA delays decision on Sarepta's muscle-wasting disorder drug "
    },
    {
        "content": "* Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date",
        "date": "05252016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics - FDA will not complete review of Eteplirsen NDA by PDUFA date "
    },
    {
        "content": "* Sabby Healthcare Master Fund  Ltd reports 5.15 percent passive stake in Sarepta Therapeutics Inc as of May 3  2016  - SEC filing  Source text - http://1.usa.gov/270EZb1 Further company coverage:",
        "date": "05062016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sabby Healthcare Master Fund reports 5.15 pct passive stake in Sarepta Therapeutics - SEC filing "
    },
    {
        "content": "* Sarepta Therapeutics announces first quarter 2016 financial results and recent corporate developments",
        "date": "05052016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics posts Q1 adj. loss per share $1.15 "
    },
    {
        "content": "* Q1 loss per share $1.31 - sec filing  Source text: (http://1.usa.gov/1WKBXCI) Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05052016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta Therapeutics Q1 loss per share $1.31 "
    },
    {
        "content": "* Sarepta issues statement on advisory committee outcome for use of Eteplirsen in treatment of duchenne muscular dystrophy",
        "date": "04262016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "BRIEF-Sarepta statement on advisory committee outcome for use of Eteplirsen in treatment of Duchenne muscular dystrophy "
    },
    {
        "content": "An experimental drug to treat Duchenne muscular dystrophy  a devastating degenerative disease that mostly affects boys  has not been proven effective  a U.S. advisory panel concluded on Monday.",
        "date": "04262016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "U.S. panel: Sarepta Duchenne drug not proven effective "
    },
    {
        "content": "U.S. Food and Drug Administration staff reviewers stuck by their negative assessment of Sarepta Therapeutics Inc's rare muscle disorder drug  further diminishing its chances of approval and wiping out nearly half of the company's value.",
        "date": "04212016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Sarepta shares sink as FDA staff stay sour on muscle drug "
    },
    {
        "content": "April 25 An experimental drug to treat Duchenne muscular dystrophy  a devastating degenerative disease that mostly affects boys  has not been proven effective  a U.S. advisory panel concluded on Monday.",
        "date": "04262016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 2-U.S. panel: Sarepta Duchenne drug not proven effective "
    },
    {
        "content": "* Stock tumbles 47 percent   (Adds details  analyst comments  shares)",
        "date": "04212016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 4-Sarepta shares sink as FDA staff stay sour on muscle drug "
    },
    {
        "content": "April 21 Sarepta Therapeutics Inc lost more than a third of its market value after U.S. Food and Administration staff maintained their negative outlook on the company's rare muscle wasting disorder drug on Thursday.",
        "date": "04212016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta shares sink as FDA staff stay sour on muscle disorder drug "
    },
    {
        "content": "April 25 Hundreds of patients and advocates packed a hotel ballroom in Hyattsville  Maryland on Monday to try to persuade advisors to the U.S. Food and Drug Administration to support approval of an experimental drug to treat Duchenne muscular dystrophy.",
        "date": "04252016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "U.S. FDA panel meets to discuss Sarepta muscular dystrophy drug "
    },
    {
        "content": "March 10 An independent panel of experts to the U.S. Food and Drug Administration (FDA) will discuss Sarepta Therapeutics Inc's muscle wasting drug on April 25  nearly three months after the original date.",
        "date": "03102016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "FDA sets new date for panel review of Sarepta's muscle drug "
    },
    {
        "content": "March 8 Drug developer Sarepta Therapeutics Inc  said it had not received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and would slash about 17 percent of its workforce.",
        "date": "03082016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Sarepta says yet to receive new date for panel review of muscle wasting drug "
    },
    {
        "content": "Jan 20 The U.S. Food and Drug Administration postponed a meeting of its advisory panel to review Sarepta Therapeutics Inc's drug for a rare muscle wasting disorder due to inclement weather forecast for Washington DC.",
        "date": "01202016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "FDA postpones panel meeting to review Sarepta's DMD drug "
    },
    {
        "content": "U.S. Food and Drug Administration staff said they were unconvinced about the effectiveness of Sarepta Therapeutics Inc's drug for a rare muscle wasting disorder  dealing another blow to the quest for a drug to treat the fatal disease.",
        "date": "01152016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "FDA staff unconvinced by Sarepta's muscle wasting drug "
    },
    {
        "content": "* Sarepta loses over half its market value   (Adds analyst comment  details)",
        "date": "01152016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 3-FDA staff unconvinced by Sarepta's muscle wasting drug "
    },
    {
        "content": "Jan 8 Akashi Therapeutics Inc  a U.S.-based biotech funded by DMD patient foundations  said it would get up to $100 million under a partnership with Germany's Grunenthal SA for developing a drug for the muscle-wasting disorder.",
        "date": "01082016",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "Patient-funded biotech in $100 mln funding deal for DMD drug "
    },
    {
        "content": "A Scottish man has been indicted by a federal grand jury in San Francisco for posing on Twitter as influential short-selling firms and sending bogus tweets that drove down the stock prices of two companies  in an effort to profit from illegal trading.",
        "date": "11062015",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "U.S. charges Scottish man over fake tweets that hurt stocks "
    },
    {
        "content": "Nov 5 A Scottish man has been indicted by a federal grand jury in San Francisco for posing on Twitter as influential short-selling firms and sending bogus tweets that drove down the stock prices of two companies  in an effort to profit from illegal trading.",
        "date": "11062015",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-U.S. charges Scottish man over fake tweets that hurt stocks "
    },
    {
        "content": "NEW YORK An experimental Ebola drug from Sarepta Therapeutics Inc protected six of eight lab monkeys injected with the virus  scientists from the company and the U.S. Army reported on Tuesday.",
        "date": "02102015",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "topStory",
        "symbol": "SRPT",
        "title": "Sarepta drug protects lab monkeys from Ebola "
    },
    {
        "content": "NEW YORK  Feb 10 An experimental Ebola drug from Sarepta Therapeutics Inc protected six of eight lab monkeys injected with the virus  scientists from the company and the U.S. Army reported on Tuesday.",
        "date": "02102015",
        "name": "Sarepta Therapeutics Inc",
        "news_type": "normal",
        "symbol": "SRPT",
        "title": "UPDATE 1-Sarepta drug protects lab monkeys from Ebola "
    }
]